ArchPoint Investors’s AstraZeneca AZN Stock Holding History

ArchPoint Investors’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,811	Closed	-$218K	–	75
2021 Q3	$218K	Buy	+1,811	New	+$211K	0.07%	99

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

ArchPoint Investors's AZN Position: Q4 2021 in Review

ArchPoint Investors sold out of AstraZeneca (AZN) in Q4 2021, closing a stake of 1,811 shares — an estimated $218K sold.

ArchPoint Investors first reported a position in AZN in Q3 2021 and held it in 1 quarter. The position peaked at $218K in Q3 2021. 949 funds tracked by Wall St. Rank hold AZN as of Q4 2021.

ArchPoint Investors reported no remaining AstraZeneca position as of Q4 2021 after selling out during the quarter.
ArchPoint Investors sold 1,811 AstraZeneca shares in Q4 2021, an estimated $218K.
ArchPoint Investors first reported a position in AstraZeneca in Q3 2021 and held it in 1 quarter.
ArchPoint Investors's AstraZeneca position peaked at $218K in Q3 2021.
949 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2021.

Based on ArchPoint Investors's 13F filing for Q4 2021, filed 11 Feb 2022.